Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) EBIT Margin (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed EBIT Margin for 16 consecutive years, with 241.07% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin changed N/A to 241.07% in Q3 2025 year-over-year; TTM through Sep 2025 was 235.51%, a 15171.0% decrease, with the full-year FY2024 number at 59.7%, down 2046.0% from a year prior.
  • EBIT Margin was 241.07% for Q3 2025 at NovaBay Pharmaceuticals, down from 9.87% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 0.15% in Q3 2023 to a low of 258.74% in Q4 2022.
  • A 5-year average of 83.56% and a median of 72.49% in 2021 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: tumbled -18655bps in 2022, then surged 21077bps in 2023.
  • NovaBay Pharmaceuticals' EBIT Margin stood at 72.2% in 2021, then tumbled by -258bps to 258.74% in 2022, then soared by 81bps to 47.98% in 2023, then surged by 79bps to 9.87% in 2024, then tumbled by -2341bps to 241.07% in 2025.
  • Per Business Quant, the three most recent readings for NBY's EBIT Margin are 241.07% (Q3 2025), 9.87% (Q4 2024), and 50.05% (Q2 2024).